EC grants approval for GSK’s Omjjara for treatment of myelofibrosis patients with anaemia

In a landmark decision, the European Commission has approved GSK plc's Omjjara (momelotinib), introducing a revolutionary treatment for adult myelofibrosis patients suffering from moderate to ... Read More